A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. J of Skin [Internet]. 2021 Nov. 5 [cited 2025 Jul. 3];5(6):s94. Available from: https://skin.dermsquared.com/skin/article/view/1445